-transparent.png){kind=logo}
Fas and Fas ligand (FasL) are implicated in programmed cell death or apoptosis. In the immunological field, they are particularly important in auto-immunity, graft rejection and anti-tumoral response. Fas ligand expression on thymocytes, activated T lymphocytes, and in sites of immune privilege, suggests the importance of Fas/FasL interactions in negative control of the immune response. The recent description of FasL expression by tumoral cells, represents a new mechanism of immune escape for different cancer, and has been well studied in colon adenocarcinoma.
Related Publications
A Berger, and
B Piqueras, and
F Pages, and
E Tartour, and
P H Cugnenc, and
W H Fridman
February 2006,
Cell cycle (Georgetown, Tex.),
A Berger, and
B Piqueras, and
F Pages, and
E Tartour, and
P H Cugnenc, and
W H Fridman
June 2005,
World journal of gastroenterology,
A Berger, and
B Piqueras, and
F Pages, and
E Tartour, and
P H Cugnenc, and
W H Fridman
November 2005,
Cancer research,
A Berger, and
B Piqueras, and
F Pages, and
E Tartour, and
P H Cugnenc, and
W H Fridman
September 2003,
Molecular biotechnology,
A Berger, and
B Piqueras, and
F Pages, and
E Tartour, and
P H Cugnenc, and
W H Fridman
May 1998,
Journal of immunology (Baltimore, Md. : 1950),
A Berger, and
B Piqueras, and
F Pages, and
E Tartour, and
P H Cugnenc, and
W H Fridman
November 1998,
The Journal of pathology,
A Berger, and
B Piqueras, and
F Pages, and
E Tartour, and
P H Cugnenc, and
W H Fridman
October 1999,
Clinical and experimental immunology,
A Berger, and
B Piqueras, and
F Pages, and
E Tartour, and
P H Cugnenc, and
W H Fridman
July 1998,
Research communications in molecular pathology and pharmacology,
A Berger, and
B Piqueras, and
F Pages, and
E Tartour, and
P H Cugnenc, and
W H Fridman
September 1996,
The Journal of experimental medicine,
A Berger, and
B Piqueras, and
F Pages, and
E Tartour, and
P H Cugnenc, and
W H Fridman
August 1998,
Bulletin du cancer,
